Yahoo Finance

Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab (consisting of consumables and services related to life science and applied tools), and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. and China representing the largest country concentrations.

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Thermo Fisher manufactures scientific instruments, consumables, and chemicals. It provides analytical instruments, lab equipment, software reagents, and supplies to pharmaceutical companies, hospitals, clinical diagnostic labs, universities, research institutions, and government agencies.

U.S. stocks have been all over the place on Friday morning, as futures suggested a down day ahead of the release of the latest PCE; futures then turned higher after the release and indeed stocks opened broadly higher; and then enthusiasm cooled quickly. As of midday, the S&P 500, Nasdaq Composite and Russell 2000 are lower, with the DJIA clinging to a modest gain. In other areas, crude, gold, and Bitcoin are all lower. As things stand, it looks like May will end an otherwise solid month with a dud in the final week.